EUCTR2018-000226-58-AT进行中（未招募）1 期
A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Subject is at least 18 years old (20 years old for subjects in Taiwan) at the screening visit.
- •4. The subject has a diagnosis of AS based on the Modified New York Criteria for Ankylosing Spondylitis (1984).
- •5. The subject must have a radiograph of the SI joints (AP Pelvis) documenting diagnosis of AS. Previous radiographs (up to 2 years old) can be used if they are accepted by the central reader. Otherwise, a new radiograph will be obtained at the Screening visit.
- •6. Subject has active AS Screening and Baseline (Day 1) visits defined as:
- •BASDAI score of =4; and
- •Back pain score (BASDAI Question 2) of =4.
- •7. Subject has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or is intolerant to NSAIDs
- •8. Subjects who are designated as TNFi-IR must have received at least 1, but not more than 2 approved TNF inhibiting biologic agent that was administered in accordance with its labeling recommendations and was inadequately effective after the minimum treatment times listed below and/or not tolerated after one or more doses.
- •At least 3 months of adalimumab treatment;
- •At least 3 months of etanercept treatment;
- •At least 4 infusions of infliximab;
- •At least 3 injections of golimumab;
- •At least 3 months of certolizumab treatment.
- •Intolerance is defined as having experienced a treatment-related AE (eg, infusion/injection reactions, infections, laboratory test changes, etc)
- •9. Subjects may be receiving the following csDMARDs at the time of the screening visit. These medications should be continued throughout the entire study and doses should remain unchanged. Any other DMARDs require discussion prior to enrollment with the sponsor for washout timeframe.
- •Methotrexate (MTX): Maximum dose of 20 mg/week. Minimum duration of therapy 4 months and dose stable for 4 weeks prior to first dose of investigational product. Subjects on MTX should be on an adequate and stable dose of folate supplementation per local standards/regulatory approval (eg, not less than 5 mg weekly based on folic acid, unless such doses would violate the local label guidelines or standard of care) for at least 4 weeks prior to the first dose of investigational product. Subject must not have had previous serious toxicity while on MTX and not be expected to require evaluation for possible methotrexate toxicity (eg, require a liver biopsy for methotrexate toxicity) during the study;
- •Sulfasalazine (Azulfidine®, Salazpyrin®): Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose stable for 4 weeks prior to first dose of investigational product.
- •10. Subjects who are already taking oral corticosteroids (not injectables) may participate in the study:
- •Oral corticosteroids: Subjects who are already receiving oral corticosteroids must be on a stable dose of =10 mg/day of prednisone or equivalent for 4 weeks prior to the first dose of investigational product;
- •Injected (eg, intraarticular, intramuscular, epidural or intravenous) corticosteroids must be discontinued 4 weeks prior to the first dose of investigational product;
- •Topical and intra-rectal corticosteroids will be allowed during the study.
- •11. Subject has discontinued al
排除标准
- •1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •2. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation (excluding noninterventional follow-up during the screening period).
- •3. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •4. History of known or suspected complete ankylosis of the spine. This can be determined/confirmed at the time of the SI radiograph by the central reader.
- •5. Subjects receiving any other conventional synthetic or biological DMARDs (other than those allowed), thalidomide (including previous use) and other prohibited concomitant medications.
- •6. Subjects that have been exposed to biological DMARDs other than TNF inhibitors.
- •7. Blood dyscrasias at screening or within 3 months prior to the first dose of investigational product including confirmed:
- •Hemoglobin <10 g/dL;
- •Absolute white blood cell count (WBC) <3.0 x 10^9/L (<3000 mm3);
- •Absolute neutrophil count (ANC) <1.5 x 10^9/L (<1500 mm3);
- •Absolute lymphocyte count <1.0 x 10^9/L (<1000/mm3);
- •Platelet count <100 x 10^9/L (<100,000/mm3).
- •8. Estimated Creatinine Clearance <40 mL/min based on Cockcroft Gault equation at Screening visit.
- •9. Total bilirubin, AST or ALT more than 1.5 times the upper limit of normal (ULN) at screening visit.
- •One re-testing of a laboratory-acceptable specimen (eg, appropriately labeled, within stability parameters, not hemolyzed, appropriate type (tube and reagent) and volume) is allowed of any above parameters if the abnormal lab(s) was an uncharacteristic result(s). Documentation in the source of the typical results to allow a repeat lab is required.
- •Re-test must be completed within the screening period.
- •10. History of any other autoimmune rheumatic disease.
- •11. History of an infected joint prosthesis at any time, with the prosthesis still in situ.
- •12. History of any lymphoproliferative disorder, such as Epstein Barr Virus related lymphoproliferative disease (EBV-LPD), history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
- •13. History of recurrent (more than one episode) herpes zoster or disseminated/multi-dermatomal (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
- •14. History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 3 months prior to the first dose of investigational product.
- •15. History of infection requiring antimicrobial therapy within 2 weeks prior to the first dose of investigational product.
- •16. Any prior treatment with non-B cell specific lymphocyte depleting agents/therapies (eg, alemtuzamab, efalizumab), alkylating agents (eg, cyclophosphamide or chlorambucil), or total lymphoid irradiation.
- •17. Any subject who has been vaccinated with live or attenuated
研究者
相似试验
进行中（未招募）
不适用
A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous for the F508del-CFTR MutationMedDRA version: 17.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003989-40-NLVertex Pharmaceuticals Incorporated501
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative ColitisEUCTR2018-003986-33-BEArena Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative ColitisEUCTR2018-003986-33-GBArena Pharmaceuticals, Inc.330
进行中（未招募）
不适用
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia - LVHJMen with benign prostatic hyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2008-002841-21-ITEli Lilly and Company521
进行中（未招募）
1 期
A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous for the F508del-CFTR MutationMedDRA version: 16.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003990-24-DKVertex Pharmaceuticals Incorporated501